While no detectable changes in tumorigenic behaviors were observed in response to the original osteoblast-derived CM, Lrp5-overexpressing CM (Lrp5 CM) significantly reduced the scratch-based motility in 1 day, EdU-based proliferation in 2 days, and transwell invasion in 2 days of EO771 mammary tumor cells (Figure 1B-C). This evidence concerns the gene LRP5 and breast cancer.